Invokana lawsuits have shown further movement in the court proceedings with the approval coming forth for the Plaintiff Fact Sheets along with its protocols details by the U.S. District Court, District of New Jersey. Invokana had recently made it to the news for updating the label regarding increased risk of leg and foot amputations as a new black box warning by the FDA.
Invokana had entered the market with a bang as the first SGLT2 inhibitor approved by the FDA to treat Type 2 diabetes. However, today more than 400 lawsuits are pending in the court, filed by individuals who suffered diabetic ketoacidosis, kidney damage, and other side effects due to its use.
Over the course of time, Neural IT has kept its clients happy by efficient, accurate, and timely delivery of Plaintiff Fact Sheet forms that speak of quality, with a full understanding that this step helps to streamline discovery stage by replacing formal interrogatories in large, complex litigations.
